四川易阿索医药科技

EAS Pharmaceutical is a biotechnology company based in Chengdu, China, dedicated to the development of next-generation small molecule drugs through targeted protein degradation. The company utilizes its proprietary PROTAC (Proteolysis Targeting Chimera) platform to design therapies that eliminate disease-causing proteins rather than simply inhibiting them. Its primary research focus lies in oncology and autoimmune diseases, where traditional inhibitors often face resistance or limited efficacy. The lead candidate, EA-001, is a novel BTK degrader currently being evaluated for the treatment of B-cell malignancies. By leveraging the ubiquitin-proteasome system, EAS Pharmaceutical aims to provide more durable and effective treatment options for patients with complex diseases. The company is situated in the Chengdu Tianfu International Bio-Town, benefiting from a robust regional life sciences ecosystem.